Figure 1.

A, A 74-year-old woman with metastases to lung and hilar lymph nodes received the combination of 0.3 mg bid efatutazone and 175 mg/m² paclitaxel iv every 3 weeks. She did not receive prior radiotherapy. and her tumor did not contain differentiated features. She had a RECIST-confirmed partial response that persisted from day 69 until day 175. B, Kaplan-Meier estimated proportion of patients free of progressive disease in the 0.15-mg (n = 7) and 0.3-mg (n = 6) efatutazone groups. Median time to progression was 48 vs 68 days, respectively. C, Kaplan-Meier estimated survival in the 0.15-mg (n = 7) and 0.3-mg (n = 6) efatutazone groups. Median survival was 98 vs 138 days, respectively.